

Energy Partitioning in Multicomponent Nanoscintillators for Enhanced Localized Radiotherapy

Valeria Secchi, Francesca Cova, Irene Villa, Vladimir Babin, Martin Nikl, Marcello Campione, and Angelo Monguzzi*



Cite This: <https://doi.org/10.1021/acsami.3c00853>



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

ABSTRACT: Multicomponent nanomaterials consisting of dense scintillating particles functionalized by or embedding optically active conjugated photosensitizers (PSs) for cytotoxic reactive oxygen species (ROS) have been proposed in the last decade as adjuvant agents for radiotherapy of cancer. They have been designed to make scintillation-activated sensitizers for ROS production in an aqueous environment under exposure to ionizing radiations. However, a detailed understanding of the global energy partitioning process occurring during the scintillation is still missing, in particular regarding the role of the non-radiative energy transfer between the nanoscintillator and the conjugated moieties which is usually considered crucial for the activation of PSs and therefore pivotal to enhance the therapeutic effect. We investigate this mechanism in a series of PS-functionalized scintillating nanotubes where the non-radiative energy transfer yield has been tuned by control of the intermolecular distance between the nanotube and the conjugated system. The obtained results indicate that non-radiative energy transfer has a negligible effect on the ROS sensitization efficiency, thus opening the way to the development of different architectures for breakthrough radiotherapy adjuvants to be tested in clinics.

KEYWORDS: radiotherapy, scintillators, energy transfer, singlet oxygen, nanomaterials



1. INTRODUCTION

Looking at recent research, it is clear that nanotechnology can play an important role in the biomedical science thanks to the successful development and use of nanoparticles for theranostics, diagnostics, monitoring of specific injured tissues or organs, and for the improvement in some traditional therapeutic treatments.^{1–3} This is mainly due to the advantages of nanomaterials with respect to bulk systems, such as the facile surface functionalization, the composition versatility, and their tailorable optical and magnetic properties, which allow them to respond to the specific demands of the targeted application and use. Consequently, a huge family of nanomaterials, such as metallic and semiconductor nanoparticles, metal/lanthanide oxides, and organic and hybrid systems, has been developed to be used in advanced diagnostic and imaging techniques, drug delivery strategies, or innovative therapeutic approaches against cancer and other deadly diseases,^{4–7} as demonstrated by the increasing number of nanosystems approved by the Food and Drug Administration agency.

For example, we can observe an increasingly larger use of radioluminescent nanoparticles, i.e., nanoscintillators, able to absorb and convert the ionizing radiation (x - or γ -rays) into a large number of UV–visible photons, which are exploitable to boost the efficacy of diagnostic techniques for preclinical mapping, intraoperative imaging, radiation dosimetry, and, importantly, as efficient coadjuvants in oncological thera-

pies.^{8–11} The search for innovative therapies to surpass state-of-the-art treatments is indeed still highly persistent. The standard cancer treatment options, represented by chemotherapy, radiotherapy, and surgery, are still associated with systemic side effects, disease recurrence, and drug/radioresistance of malignant cells. Among them, the radiotherapy exploits the effect of the ionizing radiation that directly damages the cellular DNA or indirectly forms cytotoxic reactive oxygen species (ROS), such as hydroxyl radicals and singlet oxygen (SO), upon interaction with the intracellular aqueous environment.^{7,12} However, radiotherapy is strongly limited by the maximum radiation dose that can be given to a tumor mass without incurring significant injuries to the adjacent tissues or organs.¹³ Modern approaches envisage the use of patient-specific dose-delivery plans or short radiation pulses to limit collateral effects,^{14,15} but these strategies do not solve the problem of absolute lack of selectivity of the ionizing radiation for the sick tissues. In this regard, the photodynamic therapy (PDT) has been proposed as an alternative to radiotherapy due to its high selectivity and

Received: January 18, 2023

Accepted: April 28, 2023




Figure 1. (a) Synthesis of multicomponent scintillating nanotubes (NTs) for PDT-enhanced radiotherapy achieved by the use of an SO (¹O₂^{*}) PS. (b) Photophysics of the sensitization of SO production under exposure to ionizing radiation. The free electrons and holes generated by interaction between the ionizing radiation and the NT recombine directly on the NT and on the PS. The latter is promoted to its excited-state singlet (S_n^{*}) or triplet (T_n^{*}) with a ratio of 1:3. The energy stored in the NT can be therefore transferred by non-radiative energy transfer (ET_{nr}) producing additional PS molecules in the S₁^{*} state. The PS molecules in the S₁^{*} state can subsequently experience intersystem crossing (ISC) that further populates the T₁^{*} state. From PS in the triplet state, the energy is transferred by a second non-radiative energy transfer step to molecular oxygen, which is promoted to its excited singlet state ¹O₂^{*}. (c) Sketch of ET_{nr} active and ET_{nr} inactive multicomponent scintillating NTs realized by incrementing the intermolecular distance between the NT and the PS molecules.

66 minimal invasiveness.¹⁶ PDT exploits indeed specific photo-
 67 sensitizer (PS) moieties which are selectively activated only by
 68 light in the presence of molecular oxygen in order to produce
 69 ROS.

70 The PDT has been utilized in the clinic for treatments of
 71 different cancer types, but despite the excellent results
 72 obtained, its clinical use is actually hindered by the shallow
 73 tissue penetration of light, especially in the visible spectral
 74 window where most of the best PSs absorb the electromagnetic
 75 radiation.^{17,18}

76 An important step forward to overcome both radiotherapy
 77 and PDT drawbacks was made in 2006, with the introduction
 78 of the concept of energy transducers to transform the energy
 79 deposited by X-rays or γ-rays into optical-range lumines-
 80 cence.¹⁹ The core of this PDT-enhanced radiotherapy is the
 81 use of luminescent dense nanoscintillators that can interact
 82 efficiently with the ionizing radiation achieving also a photon
 83 down-conversion into the visible range to activate the PSs, by
 84 both radiative and non-radiative energy transfer processes
 85 (Figure 1a).^{20–22} The presence of these nanoscintillators
 86 allows (i) the promotion of localized energy deposition in the
 87 tissue of interest and (ii) the activation of the PDT effect in
 88 deep tissues^{23–25} by means of a complex energy partitioning
 89 scheme. To date, diverse classes of inorganic dense nano-
 90 scintillators have been combined with organic PSs,²⁶ and they
 91 have been investigated both *in vitro* and *in vivo*.^{12,27} The
 92 excellent results obtained demonstrate clearly that this
 93 approach results in a synergistic therapeutic effect of
 94 radiotherapy and PDT,^{28–30} thanks to the enhanced
 95 sensitization of ROS production given by the presence of PS

systems.²⁰ Nevertheless, a complete understanding of the
 energy partitioning that occurs in the scintillation process
 among the dense nanoscintillators, the PDT agent, and the
 biological environment is still lacking. Consequently, the
 general guidelines for the design of optimized nanomaterials to
 be tested in a clinical environment are still eagerly required.

Here, we studied the role of a non-radiative energy transfer
 (ET_{nr}) process between the nanoscintillator and the PDT
 agents in the global energy partitioning mechanism. Parallel to
 the passive sensitized activation, triggered by the presence of
 the dense nanoscintillator that enhances the localized release of
 the ionizing radiation energy (Figure 1b), ET_{nr} is indeed
 usually considered a crucial activation pathway for PDT
 sensitizers,^{12,31} but no direct proof has been given yet.
 Considering that the optimization of ET_{nr} imposes several
 severe restrictions on the material composition, architecture,
 and electronic properties in order to couple effectively a
 nanoscintillator to a PS system, it is therefore crucial to
 understand its effective role in the global sensitization process
 for the design of optimized radiotherapy coadjuvants. In
 particular, we investigate a series of scintillating nanotubes
 (NTs) functionalized with a model conjugated PS for singlet
 oxygen (SO). The ET_{nr} rate and yield have been finely tuned
 by controlling the intermolecular distance between the NT and
 the chemically coupled PS molecules. The results obtained
 suggest that ET_{nr} has a minor role in the SO sensitization
 process, thus opening the way to the development of different
 architectures for highly effective radiotherapy coadjuvants to
 be tested in clinics.




Figure 2. (a) Transmission electron microscopy (TEM) image of scintillating chrysotile NTs and their size distribution (inset). (b) On the left, the PL (dashed–dotted line, exc. 250 nm) and radioluminescence (RL, solid line) spectrum of the NT under soft X-ray exposure (dashed–dotted line). On the right, absorption (dashed line) and PL (solid line) spectra of the conjugated chromophore Rhodamine Red C₂ maleimide selected as the model SO PS. (c) Attenuated reflectance FT-IR spectra of NTs and the multicomponent nanosciintillator series obtained by tuning the PS-to-NT intermolecular distance from 5 Å (NT-5*) to 46 Å (NT-46*). The asterisks mark the sample where Rhodamine Red C₂ maleimide is substituted with rhodamine B. Shaded areas mark the characteristic IR mode of the NT (gray at around 1000 and 4700 cm⁻¹) and of the PS (orange, 2300–2500 cm⁻¹). (d) PL of multicomponent nanosciintillators as a function of the NT-to-PS intermolecular distance under UV excitation at 250 nm. (e) PL intensity decay in time recorded at 430 nm under pulsed excitation at 250 nm of NTs and the functionalized NT sample series. The inset is a digital picture of the NT-20 sample under daylight.

2. RESULTS AND DISCUSSION

As detailed in the [Experimental Methods](#) section, the PS-functionalized nanosciintillators have been realized by coupling biocompatible chrysotile NTs to the conjugated chromophore Rhodamine Red C₂ maleimide by means of several heterobifunctional bridges of different lengths ([Figure 1a](#), see Supporting Information file, [Table S1](#), Supporting [Figure S1](#)). The NTs have been synthesized in aqueous solution under hydrothermal conditions in the presence of Mg and Si precursors. We obtained pure chrysotile NTs ([Figure S2](#)) of diameter 50 nm and average length 100 nm ([Figure 2a](#)) with a blue scintillation and photoluminescence (PL) peaked at 430 nm ([Figure 2b](#)). The external surface of the NTs is brucitic,³² showing a positive ζ -potential which allows the coulombic interaction with anionic species such as the carboxyl functional group at one end of the bridge ligand series employed ([Figure 1a](#)). The PS system has been selected because of (i) a suitable energetic resonance between its ground state absorption and the NT scintillation emission ([Figure 2b](#)), which allows the occurrence of non-radiative ET_{nr} by both the Dexter and Förster mechanisms between the NT and the PS molecules,³³ and (ii) the presence of the maleimide functionality. The latter is a crucial point because this functionality allows us to exploit the thiol–maleimide click reaction with the –SH functional group at one end of the NT surface ligand to anchor the PS ([Figure 1a](#)), therefore controlling their composition.^{34,35} So, although the resonance with the NT emission is not ideal, the employed PS is the ideal system to perform the designed experiments. In such a way, by varying the length of the connecting ligand, we can tune the rate and yield of ET_{nr} by increasing the intermolecular distance between the NT and PS from 17 to 37 Å ([Table S1](#)). The different samples are labeled

as NT-*x*, where *x* is the distance between the NT and the PS expressed in angstroms. It is worth noting that the organic ligand employed is not rigid; so, the considered intermolecular distances are nominal values taken as the reference. To have also very short or very large intermolecular distances of 5 and 46 Å, we used as the PS the conjugated chromophore rhodamine B ([Figure S1](#)) that possesses the right anionic functionality to be directly anchored on the NT surface (NT-5*)^{36,37} or placed quite far by using polyethylene glycol as the connecting ligand (NT-46*). Considering the typical non-radiative interaction radii and the poor luminescence yield of NTs,³³ in sample NT-5*, the ET_{nr} yield ϕ_{ET}^{nr} should be maximized while minimized in the sample NT-46*. In the latter case, given the limited energetic resonance between NT emission and PS absorption, the contribution of ET_{nr} to the SO sensitization can be for sure neglected and therefore completely decoupled from the other mechanisms involved ([Figure 1b](#)).

The successful functionalization of the NT surfaces with the heterobifunctional chains and fluorescent PS molecules has been confirmed by means of vibrational and optical spectroscopy experiments. [Figure 2c](#) reports the infrared spectra of the bare NTs and the NT-*x* sample series. In all spectra, we can observe the main chrysotile vibrational peaks located at around 3700 cm⁻¹ (MgOH stretching) and in the region around 1000 cm⁻¹ (Si–O–Mg, Si–O–Si, and Si–O stretching).³⁷ Furthermore, the spectra of the samples from NT-17 to NT-37 show clearly the peaks related to the Rhodamine Red C₂ maleimide or to the rhodamine B functionalities (the C=C stretching vibrations at 1628 and 1542 cm⁻¹, the N–C bending at 1291 cm⁻¹, and the C–H stretching in the region around 3000 cm⁻¹).^{38,39} The average number of PS molecules




Figure 3. (a) RL spectra of the multicomponent nanoscintillator series as a function of the PS-to-NT intermolecular distance, normalized to the residual PS emission intensity. (b) Scintillation pulses recorded at ca. 620 nm under pulsed X-ray excitation at 40 keV. (c) PL intensity decay at 620 nm under pulsed excitation at 250 nm. (d) Relative increment of the SO concentration as a function of the irradiation time under soft X-rays for the NT-20 sample (4.0 mg/mL, PBS). The SO increment has been monitored by recording the SO optical probe SOSG under simultaneous CW laser excitation at 473 nm (inset). (e) NT-to-PS energy transfer yield (ϕ_{ET}^{nr} , dots), relative scintillation yield ($\bar{\phi}_{scint}^{PS}$) of the PS, and SO relative sensitization ability $\bar{\phi}_{SO}$ after 600 s of exposure to soft X-rays for the multicomponent nanoscintillator series, as a function of the NT-to-PS intermolecular distance. Error bars are put as the mean standard deviation calculated on a $N = 3$ measurement replica.

188 $\langle n \rangle$ coupled to each NT has been evaluated by means of
 189 optical absorption measurements (Table S1, Figure S1). Under
 190 UV excitation at 250 nm, all the functionalized NTs show a
 191 multiband PL spectrum (Figure 2d) where a residual NT
 192 emission at 430 nm can be observed, even very weak in some
 193 cases due to the occurrence of ET_{nr} . The PS fluorescence around
 194 600 nm from the Rhodamine Red C₂ maleimide and at 580 nm
 195 from the rhodamine B can be clearly distinguished in samples
 196 NT-17–NT-37 and samples NT-5* and NT-46*, respectively.
 197 No change in the emission properties is observed after keeping
 198 NT- x in a phosphate buffered saline (PBS) dispersion for up to
 199 6 months, thus demonstrating the excellent stability of the
 200 synthesized materials. The residual NT PL intensity at 430 nm
 201 increases as a function of the NT-to-PS distance, thus
 202 suggesting the progressive reduction of ϕ_{ET}^{nr} by separating the
 203 NT from the PS. ϕ_{ET}^{nr} has been quantitatively evaluated by
 204 means of time-resolved PL experiments. Figure 2e shows the
 205 PL intensity decay in time of the samples monitored at 430 nm
 206 as a function of the NT-to-PS intermolecular distance. As
 207 expected, the emission decay accelerates by shortening the
 208 intermolecular distance that increases the ET_{nr} rate, which
 209 becomes competitive with the spontaneous recombination of
 210 the NT excited state.³³ Both the bare NTs and the NT- x
 211 sample series show emission intensity decays with a multi-
 212 exponential behavior. The characteristic lifetime is calculated
 213 as the average emission lifetime $\langle \tau_x \rangle$ (Table S1). The ϕ_{ET}^{nr}
 214 value is then calculated as $\phi_{ET}^{nr} = 1 - \langle \tau_x \rangle / \langle \tau_{NT} \rangle$, where $\langle \tau_{NT} \rangle$
 215 is the average lifetime of the bare NT emission. ϕ_{ET}^{nr} is reduced

from 70% down to 10% by increasing the NT-to-PS nominal 216
 intermolecular distance from 5 to 46 Å (vide infra, Figure 3e). 217

Figure 3a shows the RL spectra of the NT and NT- x sample 218
 series powders (16 mg) recorded under steady-state excitation 219
 by soft X-rays (Experimental Methods). Similar to the PL 220
 spectra, also in this case, we can observe clearly the typical PS 221
 luminescence with a residual blue luminescence from NTs. 222
 The relative scintillation yield of the PS dyes $\bar{\phi}_{scint}^{PS}$ is taken as 223
 the RL intensity integrated in the PS emission spectral range 224
 (I_{RL}^{PS}). Notably, the PS scintillation luminescence is slightly red- 225
 shifted with respect to the PL spectrum in dispersion due to the 226
 enhanced self-absorption of dyes and the possible 227
 formation of aggregates in the powder form. Figure 3b 228
 shows the corresponding scintillation pulses recorded at the 229
 dye emission wavelength by exposing the powders to a pulsed 230
 X-ray source (Experimental Methods, Table S2). This 231
 experiment has been performed to have a hint on the 232
 luminescence properties of the materials under exposure to 233
 ionizing radiation. These measurements have been performed 234
 on powders because the pulsed X-ray source irradiance is too 235
 weak to record reliable signals from the diluted aqueous 236
 suspensions employed to generate the SO. For the samples 237
 from NT-5* to NT-24, the scintillation pulse lifetime is around 238
 3 ns, with no significant differences. The observed values are 239
 slightly higher with respect to the corresponding PS PL decay 240
 time (Figure S3), in agreement with the possible self- 241
 absorption delay effect of the dye on the apparent emission 242
 lifetime. On the other side, the formation of low-energy J- 243

aggregates is most probably responsible for the longer-emission component in the scintillation of samples NT-30, NT-37, and NT-46* and for the fast quenching observed in samples NT-37 and NT-46*.³⁶ The more marked presence of aggregates in these samples agrees with the presence of long and more flexible surface ligands, which allows the connected dyes to interact more freely with respect to the NT functionalized with shorter ligands, which keep the dyes far enough to limit detrimental intermolecular interactions, especially in the powder form.

On the other hand, considering that the NT will be used in diluted aqueous dispersion, for a quantitative and reliable comparison between the different samples, we have measured the recombination kinetics of PS PL in the aqueous dispersion where they will be used to sensitize the SO production. Figure 3c reports the NT-*x* PL intensity decay with time recorded at 610 nm under pulsed laser excitation at 250 nm (Experimental Methods). In all cases, we observe an average decay time shorter than the one observed for the single chromophore in diluted solution (Figure S4), again most probably due to the presence of quenching J-aggregates on the NT surface, but there is no evident coherent trend. In some cases, the emission intensity decays as a single exponential function in a time shorter than the spontaneous one (1.97 ns for Rhodamine Red C₂ maleimide and 2.71 ns for rhodamine B, Figure S4), while in some cases, we observe also a multi-exponential decay behavior (N-17, NT-19, and NT-37). Nevertheless, independently from its origin, the observed partial emission quenching suggests that upon functionalization, the PL yield $\phi_{\text{pl}}^{\text{PS}}$ (Experimental Methods, Table S3) of the PS is reduced. This means that the recombination properties of the PS singlet excited state are modified upon binding to NTs, including the intersystem crossing (ISC) rate that populates the triplet state from which the SO sensitization occurs by energy transfer to the ground-state molecular oxygen in solution (Figure 1b)¹⁷ and the triplet state lifetime that also affects the transfer to molecular oxygen. Therefore, also, the SO generation efficiency can be affected. This effect has been taken into account (vide infra) in order to have a reliable relative comparison of the samples ϕ_{SO} .

ϕ_{SO} has been directly observed by the measurement of the relative SO production efficiency under soft X-ray exposure. Figure 3c reports the evolution of the SO concentration in PBS dispersion of NT-20, as an example, which has been monitored in situ by using the SO Sensor Green (SOSG, Experimental Methods) as an optical probe.²⁰ The SOSG PL intensity is proportional to the concentration of SO;⁴⁰ thus, upon its selective excitation, we can compare the evolution of the SO concentration as a function of time (inset of Figures 3c and S5). Specifically, ϕ_{SO} is defined here as the relative increment of the SO concentration and calculated as $\phi_{\text{SO}} = 100 \times [I_{\text{pl}}^{\text{SOSG}}(t) - I_{\text{pl}}^{\text{SOSG}}(0)]/I_{\text{pl}}^{\text{SOSG}}(0)$. All the samples in the series have been monitored under steady-state X-rays exposure up to 600 s which corresponds to a delivered dose of approximately 260 Gy, in glass vials. All the samples show a SO sensitization ability (Figure S4). In order to have a reliable relative comparison, the SO sensitization efficacy is finally calculated as a relative normalized SO sensitization ability $\bar{\phi}_{\text{SO}} = \frac{\phi_{\text{SO}}}{(n)\phi_{\text{pl}}^{\text{PS}}}$, thus taking into account the perturbation of the PS observed upon binding that is assumed to modify its $\phi_{\text{pl}}^{\text{PS}}$ and thus indirectly the SO ability.⁴¹

The comparative analysis among the observed $\phi_{\text{ET}}^{\text{nr}}$, $\bar{\phi}_{\text{scint}}^{\text{PS}}$ and $\bar{\phi}_{\text{SO}}$ as a function of surface ligand length is reported in Figure 3e. It is worth noting that the absorption of the PS molecules in the investigated dispersions is very low (Figure S8), and the NT emission efficiency is very weak ($\ll 5\%$) so that we can exclude a priori a relevant photoexcitation of the conjugated PS by direct absorption of the NT scintillation light (i.e., radiative energy transfer). As discussed above, the $\phi_{\text{ET}}^{\text{nr}}$ value decreases by about 1 order of magnitude by moving progressively far away the PS molecules from the scintillating NT, until a $\phi_{\text{ET}}^{\text{nr}} = 10\%$ is observed in the NT-46* sample in agreement with the distance-dependent behavior of the non-radiative ET_{nr} rate. On the other side, both $\bar{\phi}_{\text{scint}}^{\text{PS}}$ and $\bar{\phi}_{\text{SO}}$ show a substantially constant behavior completely uncorrelated to $\phi_{\text{ET}}^{\text{nr}}$, thus suggesting that the scintillation light output and the efficiency of the SO sensitizer are independent from the system architecture. Even in the best configuration with $\phi_{\text{ET}}^{\text{nr}} = 70\%$, no enhancement is observed in the SO production. Similar results are observed by using a different optical probe for the SO formation (Figures S6 and S7). These findings demonstrate therefore the negligible role of ET_{nr} between the nanoscintillator NTs and the PS moiety in activating the SO sensitization ability of multicomponent materials for PDT-enhanced radiotherapy. Moreover, these results confirm experimentally for the first time the output of radiation/matter interaction simulations in nanoscintillators recently proposed.⁴² According to the dimension of our nanoscintillators, only a minor fraction of the energy deposited upon interaction of the X-rays with the high-Z elements is stored in the particle itself, while most of the energy is spread around the particle by generating a swarm of secondary charges that can diffuse for distance up to hundreds of nanometers. Thus, even in the best case where $\phi_{\text{ET}}^{\text{nr}}$ equals unity, the effective boosting of the PDT activity due to the ET_{nr} channel can be only negligible, while the major role in the global energy partitioning process is played by the direct recombination of free charges on the PSs, which is locally sensitized by the presence of the dense nanoscintillator.

3. CONCLUSIONS

In conclusion, we successfully realized a series of multi-component nanoscintillators as a model system for PDT-enhanced radiotherapy coadjuvants. Their architecture has been finely tailored in order to control the efficiency of the non-radiative energy transfer process between the building blocks of the multicomponent system, namely, the scintillating dense nanoparticle, responsible for the localized interaction with the ionizing radiation, and the attached ROS-sensitizing PS species that enable the PDT. The obtained results demonstrate that the non-radiative energy transfer plays a marginal role in the global energy partitioning process responsible for the evident synergistic effect of radiotherapy and deep-tissue X-ray-activated PDT usually observed during cancer treatment using these materials. This finding has important consequences, by pointing out some new guideline pivotal for the design and realization of optimized multi-component radiotherapy coadjuvants. First, the matching between the electronic transitions of the scintillator and the PS is no more strictly required since the PS is mainly activated by direct recombination of the free charges produced during the primary and secondary interaction events in the

364 scintillation process. This strongly relaxes the constraints on
365 the type of PS that can be used. Second, the close packing of
366 scintillators and PSs is no more required to maximize the
367 energy transfer rate, thus again significantly relaxing the
368 constraints on the system architectures and avoiding the
369 problems originating from the need for specific control of
370 intermolecular interactions between close-packed species.
371 Third, considering that heaviest elements such as lead could
372 represent a critical issue for their poor biocompatibility, the
373 obtained results indicate that larger but still biocompatible
374 nanoparticles are required to maximize the local radio-
375 sensitization effect in tumors. For example, hafnia and/or
376 zirconia nanoparticles^{7,42,43} with size up to 100–200 nm can
377 be envisaged. According to the obtained results, the best
378 arrangement for the PS moiety could be, for example, a shell
379 wrapped around the dense nanoparticle with thickness up to
380 100 nm, in order to harvest the most of the diffusing charge
381 energy. This design will result in a bigger multicomponent
382 system with still good cellular uptake and delivery in the
383 body^{27,44–47} and a simultaneous good interaction with the
384 ionizing radiations and optimized energy harvesting and
385 partitioning that will potentially lead to a breakthrough
386 increment of the radiotherapy effect even at low doses.

4. EXPERIMENTAL SECTION

4.1. Synthesis of Stoichiometric Chrysotile Nanotubes.

387 Chrysotile NTs were synthesized according to a previously used
388 synthetic method.²⁰ A hydrothermal reactor with a 100 cm³
389 polypropylene vessel was used to carry out the hydrothermal reaction
391 of 1522 mg of Na₂SiO₃ and 764 mg of MgCl₂ in an aqueous solution
392 of NaOH (220 mL 0.4 M) at 250 °C with a run duration of 16 h. The
393 precipitate removed from the solution was repeatedly washed with
394 deionized water before being dried for 3 h at 110 °C.

4.2. Functionalization of Chrysotile Nanotubes with Chains of Different Lengths.

395 For the preparation of each sample, 100 mg
396 of NT powder was suspended in 25 mL of PBS and 30 mg of 16-
397 mercaptohexadecanoic acid suspended in 25 mL of PBS or 40 mg of
398 11-mercaptoundecanoic acid suspended in 20 mL of PBS or 810 μL of
399 8 mercaptooctanoic acid, or 600 μL of 3 mercaptopropionic acid, or
401 120 mg of L-cysteine suspended in 25 mL of PBS, or 620 μL of
402 thioglycolic acid were added slowly under stirring for 10 min. Samples
403 were centrifuged for 5 min at 6500 rpm. The precipitate removed
404 from the solution was repeatedly washed with deionized water before
405 being dried for 3 h at 50 °C.

4.3. Functionalization of NTs + Variable Length Chain with Invitrogen Rhodamine Red C₂ Maleimide.

406 40 mg of NTs
407 functionalized with chains of different lengths was dispersed in 5 mL
408 of tris(hydroxymethyl)aminomethane (TRIS), and 4 mL of
409 Invitrogen Rhodamine Red C₂ maleimide (1.4 mg in 70 mL of
410 TRIS) was added in the solution. Maleimide is a thiol-reactive probe
411 and reacts with thiol groups in a typical thiol–maleimide “click”
412 chemistry reaction to give thioether-coupled products. Samples were
413 centrifuged for 5 min at 6500 rpm. The precipitate removed from the
414 solution was repeatedly washed with deionized water and PBS before
415 being dried for 3 h at 50 °C.

4.4. Functionalization of Chrysotile Nanotubes with Rhodamine B.

416 60 mg of NTs was dispersed in 15 mL of PBS, and 2 mL of
417 rhodamine B (3 × 10⁻⁵ M in PBS) was added in the solution. Samples
418 were centrifuged for 5 min at 6500 rpm. The precipitate removed
419 from the solution was repeatedly washed with deionized water and
420 PBS before being dried for 3 h at 50 °C.

4.5. Functionalization of Chrysotile Nanotubes with Rhodamine B-PEG2k-COOH (Sigma-Aldrich).

421 60 mg of NTs was dispersed in 15 mL of PBS, and 2 mL of rhodamine B-
422 PEG2k-COOH (2 mg/7 mL PBS) was added in the solution. Samples were
423 centrifuged for 5 min at 6500 rpm. The precipitate removed from the

424 solution was repeatedly washed with deionized water and PBS before
425 being dried for 3 h at 50 °C.

426 **4.6. Diffraction Experiment (XRD).** Powder X-ray diffraction
427 patterns were acquired in Bragg–Brentano geometry with Cu Kα
428 radiation (analytical X'Pert Pro powder diffractometer).

429 **4.7. Transmission Electron Microscopy.** Transmission electron
430 microscopy (TEM) observations have been performed with a JEOL
431 JEM1220. TEM samples were prepared by dispersing a few milligrams
432 of the compounds in 2 mL of distilled water and dropping 3 μL of
433 solution on carbon-coated copper grids.

434 **4.8. Attenuated Total Reflection Fourier-Transform Infrared Spectroscopy.** Attenuated total reflection Fourier-transform infrared
435 spectroscopy spectra of dried samples were obtained on a Thermo
436 Scientific Nicolet iS20 FTIR spectrometer.

437 **4.9. Optical Studies.** Absorption spectra were recorded using a
438 Cary Lambda 900 spectrophotometer at normal incidence with
439 Suprasil quartz cuvettes with a 0.1 cm optical path length. Steady-state
440 PL and PL excitation spectra have been recorded using a xenon lamp
441 as an excitation source, together with a double monochromator
442 (Jobin-Yvon Gemini 180 with a 1200 grooves/mm grating), and
443 recorded through a nitrogen-cooled charge-coupled device (CCD)
444 detector coupled to a monochromator (Jobin-Yvon Micro HR).
445 Under cw laser excitation, signals have been recorded using a
446 nitrogen-cooled CCD coupled with a double monochromator, Triax-
447 190 (HORIBA Jobin-Yvon), with a spectral resolution of 0.5 nm. All
448 spectra have been corrected for the setup optical response. Time-
449 resolved PL spectra have been recorded using a pulsed light-emitting
450 diode (LED) at 250 nm (3.65 eV, EP-LED 340 Edinburgh
451 Instruments, a pulse width of 700 ps) or a pulsed laser at 405 nm
452 (3.06 eV, EPL-405 Edinburgh Instruments, a pulse width of 150 ps)
453 as a light source. Data were obtained with an Edinburgh Instruments
454 FLS-980 spectrophotometer, with a 5 nm bandwidth and a time
455 resolution of 0.1 ns.

456 **4.10. Radioluminescence Experiments.** RL measurements
457 were performed by irradiating the samples at room temperature
458 with Philips 2274 (steady-state RL spectroscopy) or a Machlett OEG
459 50 (SO production monitoring experiment) X-ray tubes, both with a
460 tungsten target, equipped with a beryllium window and operated at 20
461 kV and 20 mA. At this voltage, X-rays are generated by the
462 bremsstrahlung mechanism superimposed onto the L and M
463 transition lines of tungsten due to the impact of electrons generated
464 through the thermionic effect and accelerated onto a tungsten target.
465 No beam filtering has been applied. RL spectra have been recorded
466 using a homemade apparatus featuring a liquid nitrogen-cooled CCD
467 (Jobin-Yvon Symphony II) coupled to a monochromator (Jobin-Yvon
468 Triax 180) with a 100 grooves/mm grating as the detection system.
469 The spectra were corrected for the setup optical response. For RL
470 experiments, the NT-*x* powder was used to fill small aluminum
471 crucibles of 1 mm thickness to completely absorb the incident X-rays.
472 Therefore, in all samples, we have the same amount of deposited
473 energy. Therefore, $\overline{\phi}_{\text{scint}}^{\text{PS}}$ is directly given by the ratio of the integrated
474 intensity of the RL spectra.

475 **4.11. Scintillation Experiments.** Scintillation decays under
476 pulsing X-ray excitation were measured at room temperature using
477 picosecond (ps) X-ray tube N5084 (Hamamatsu Photonics, Japan) at
478 40 kV. The X-ray tube was driven by the ps light pulse from a laser
479 with a repetition rate of up to 1 MHz. The signal was detected by a
480 hybrid ps photon detector and Fluorohub unit (Horiba Scientific,
481 Japan). The setup instrumental response function full width at half-
482 maximum was about 70 ps. The scintillation decay curves were
483 detected using a high-pass filter for the range above 580 nm. The
484 emission was monitored from the same sample's surface where it was
485 excited.

486 **4.12. SO Relative Concentration Measurement.** The optical
487 probe SOSG has been purchased from Thermo Fisher and used as is.
488 The SOSG powder has been diluted in a 1:10 solution of dimethyl
489 sulfoxide and PBS, which has been used to disperse the NTs with a
490 concentration of 4 mg/mL. The intensity of the SOSG fluorescence,
491 which is directly proportional to the concentration of SO in the

497 environment, has been monitored during the X-ray exposure under
498 continuous-wavelength laser light excitation at 473 nm. The
499 integrated SOSG PL is then proportional to the amount of SO
500 produced upon irradiation. The SOSG emission intensity was
501 integrated between 500 and 530 nm, in order to avoid inclusion of
502 the emission of the PSs. The measured values have been corrected by
503 the dye quantum yield, by the relative intrinsic efficiency of SO
504 generation of the two rhodamines (Figure S2), and by the average
505 number of dyes per NT..

506 ■ ASSOCIATED CONTENT

507 ■ Supporting Information

508 The Supporting Information is available free of charge at
509 <https://pubs.acs.org/doi/10.1021/acsami.3c00853>.

510 Optical, scintillation, and SO sensitization experiments
511 (PDF)

512 ■ AUTHOR INFORMATION

513 Corresponding Author

514 **Angelo Monguzzi** – Dipartimento di Scienza Dei Materiali,
515 Università; Degli Studi Milano-Bicocca, 20125 Milano, Italy;
516 NANOMIB, Center for Biomedical Nanomedicine, University
517 of Milano-Bicocca, 20126 Milan, Italy; orcid.org/0000-0001-9768-4573; Email: angelo.monguzzi@unimib.it

519 Authors

520 **Valeria Secchi** – Dipartimento di Scienza Dei Materiali,
521 Università; Degli Studi Milano-Bicocca, 20125 Milano, Italy;
522 NANOMIB, Center for Biomedical Nanomedicine, University
523 of Milano-Bicocca, 20126 Milan, Italy

524 **Francesca Cova** – Dipartimento di Scienza Dei Materiali,
525 Università; Degli Studi Milano-Bicocca, 20125 Milano,
526 Italy; orcid.org/0000-0001-7367-109X

527 **Irene Villa** – FZU—Institute of Physics of the Czech Academy
528 of Sciences, 16 200 Prague, Czech Republic; Dipartimento di
529 Scienza Dei Materiali, Università; Degli Studi Milano-
530 Bicocca, 20125 Milano, Italy; orcid.org/0000-0002-6150-7847

532 **Vladimir Babin** – FZU—Institute of Physics of the Czech
533 Academy of Sciences, 16 200 Prague, Czech Republic;
534 orcid.org/0000-0003-3072-2242

535 **Martin Nikl** – FZU—Institute of Physics of the Czech
536 Academy of Sciences, 16 200 Prague, Czech Republic;
537 orcid.org/0000-0002-2378-208X

538 **Marcello Campione** – Department of Earth and
539 Environmental Sciences, Università; Degli Studi Milano-
540 Bicocca, 20126 Milano, Italy; NANOMIB, Center for
541 Biomedical Nanomedicine, University of Milano-Bicocca,
542 20126 Milan, Italy; orcid.org/0000-0001-5627-6186

543 Complete contact information is available at:
544 <https://pubs.acs.org/10.1021/acsami.3c00853>

545 Notes

546 The authors declare no competing financial interest.

547 ■ ACKNOWLEDGMENTS

548 This work has been supported by the Italian Ministero degli
549 Affari Esteri e della Cooperazione Internazionale (MAECI)
550 Project X-PATH 2020-H45H19000070001, by the Ministero
551 della Salute (project code RF-2016-02362263, NanoTrack-
552 EXO), by the Marie Skłodowska-Curie Actions Widening
553 Fellowships (MSCA-WF) grant no. 101003405—HANSOME,
554 and by the Operational Programme Research, Development

and Education financed by European Structural and Invest-
ment Funds and the Czech Ministry of Education, Youth and
Sports—Project no. SOLID21 CZ.02.1.01/0.0/0.0/16_019/
0000760.

559 ■ REFERENCES

- (1) Haque, S.; Whittaker, M. R.; McIntosh, M. P.; Pouton, C. W.; Kaminskas, L. M. Disposition and safety of inhaled biodegradable nanomedicines: Opportunities and challenges. *Nanomedicine* **2016**, *12*, 1703–1724.
- (2) Teleanu, D. M.; Chircov, C.; Grumezescu, A. M.; Teleanu, R. I. Neuronanomedicine: An up-to-date Overview. *Pharmaceutics* **2019**, *11*, 101.
- (3) Liu, Y.; Zhao, G.; Xu, C.-F.; Luo, Y.-L.; Lu, Z.-D.; Wang, J. Systemic Delivery of CRISPR/Cas9 with PEG-PLGA Nanoparticles for Chronic Myeloid Leukemia Targeted Therapy. *Biomater. Sci.* **2018**, *6*, 1592–1603.
- (4) Dong, H.; Du, S.-R.; Zheng, X.-Y.; Lyu, G.-M.; Sun, L.-D.; Li, L.-D.; Zhang, P.-Z.; Zhang, C.; Yan, C.-H. Lanthanide Nanoparticles: from Design toward Bioimaging and Therapy. *Chem. Rev.* **2015**, *115*, 10725–10815.
- (5) Zarschler, K.; Rocks, L.; Licciardello, N.; Boselli, L.; Polo, E.; Garcia, K. P.; De Cola, L.; Stephan, H.; Dawson, K. A. Ultrasmall inorganic nanoparticles: State-of-the-art and perspectives for biomedical applications. *Nanomedicine* **2016**, *12*, 1663–1701.
- (6) Li, M.; Luo, Z.; Zhao, Y. J. C. o. M. Self-assembled Hybrid Nanostructures: versatile Multifunctional Nanoplatforams for Cancer Diagnosis and Therapy. *Chem. Mater.* **2018**, *30*, 25–53.
- (7) Lu, K.; He, C.; Guo, N.; Chan, C.; Ni, K.; Lan, G.; Tang, H.; Pelizzari, C.; Fu, Y.-X.; Spiotto, M. T.; et al. Low-dose X-ray Radiotherapy—radiodynamic Therapy via Nanoscale Metal—organic Frameworks enhances Checkpoint Blockade Immunotherapy. *Nat. Biomed. Eng.* **2018**, *2*, 600–610.
- (8) Alqathami, M.; Blencowe, A.; Yeo, U. J.; Doran, S. J.; Qiao, G.; Geso, M. Novel Multicompartment 3-dimensional Radiochromic Radiation Dosimeters for Nanoparticle-enhanced Radiation Therapy Dosimetry. *Int. J. Radiat. Oncol.* **2012**, *84*, e549–e555.
- (9) Shaffer, T. M.; Drain, C. M.; Grimm, J. J. Optical Imaging of Ionizing Radiation from Clinical Sources. *J. Nucl. Med.* **2016**, *57*, 1661–1666.
- (10) Chen, X.; Song, J.; Chen, X.; Yang, H. X-ray-activated Nanosystems for Theranostic Applications. *Chem. Soc. Rev.* **2019**, *48*, 3073–3101.
- (11) Crapanzano, R.; Secchi, V.; Villa, I. Co-adjuvant Nanoparticles for Radiotherapy Treatments of Oncological Diseases. *Appl. Sci.* **2021**, *11*, 7073.
- (12) Sun, W.; Zhou, Z.; Prax, G.; Chen, X.; Chen, H. Nanoscintillator-mediated X-ray induced Photodynamic Therapy for Deep-seated Tumors: from Concept to Biomedical Applications. *Theranostics* **2020**, *10*, 1296–1318.
- (13) Bulin, A.-L.; Broekgaarden, M.; Simeone, D.; Hasan, T. Low dose Photodynamic Therapy harmonizes with Radiation Therapy to induce Beneficial Effects on Pancreatic Heterocellular Spheroids. *Oncotarget* **2019**, *10*, 2625–2643.
- (14) Esposito, M.; Villaggi, E.; Bresciani, S.; Cilla, S.; Falco, M. D.; Garibaldi, C.; Russo, S.; Talamonti, C.; Stasi, M.; Mancosu, P. Estimating Dose Delivery Accuracy in Stereotactic Body Radiation Therapy: a Review of in-vivo Measurement Methods. *Radiother. Oncol.* **2020**, *149*, 158–167.
- (15) Vozenin, M.-C.; Bourhis, J.; Durante, M. Towards Clinical Translation of FLASH Radiotherapy. *Nat. Rev. Clin. Oncol.* **2022**, *19*, 791–803.
- (16) Dolmans, D. E. J. G. J.; Fukumura, D.; Jain, R. K. Photodynamic Therapy for Cancer. *Nat. Rev. Cancer* **2003**, *3*, 380–387.
- (17) DeRosa, M. C.; Crutchley, R. J. Photosensitized Singlet Oxygen and its Applications. *Coord. Chem. Rev.* **2002**, *233–234*, 351–371.

- 621 (18) Agostinis, P.; Berg, K.; Cengel, K. A.; Foster, T. H.; Girotti, A.
622 W.; Gollnick, S. O.; Hahn, S. M.; Hamblin, M. R.; Juzeniene, A.;
623 Kessel, D.; Korbek, M.; Moan, J.; Mroz, P.; Nowis, D.; Piette, J.;
624 Wilson, B. C.; Golab, J. Photodynamic Therapy of Cancer: An update.
625 *Ca-Cancer J. Clin.* **2011**, *61*, 250–281.
- 626 (19) Chen, W.; Zhang, J. Using Nanoparticles to Enable
627 Simultaneous Radiation and Photodynamic Therapies for Cancer
628 Treatment. *J. Nanosci. Nanotechnol.* **2006**, *6*, 1159–1166.
- 629 (20) Villa, I.; Villa, C.; Crapanzano, R.; Secchi, V.; Tawfilas, M.;
630 Trombetta, E.; Porretti, L.; Brambilla, A.; Campione, M.; Torrente,
631 Y.; Vedda, A.; Monguzzi, A. Functionalized Scintillating Nanotubes
632 for Simultaneous Radio- and Photodynamic Therapy of Cancer. *ACS*
633 *Appl. Mater. Interfaces* **2021**, *13*, 12997–13008.
- 634 (21) Lu, L.; Sun, M.; Wu, T.; Lu, Q.; Chen, B.; Huang, B. All-
635 inorganic Perovskite Nanocrystals: Next-generation Scintillation
636 Materials for High-resolution X-ray Imaging. *Nanoscale Adv.* **2022**,
637 *4*, 680–696.
- 638 (22) Secchi, V.; Monguzzi, A.; Villa, I. Design Principles of Hybrid
639 Nanomaterials for Radiotherapy Enhanced by Photodynamic
640 Therapy. *Int. J. Mol. Sci.* **2022**, *23*, 8736.
- 641 (23) Chen, H.; Wang, G. D.; Chuang, Y.-J.; Zhen, Z.; Chen, X.;
642 Biddinger, P.; Hao, Z.; Liu, F.; Shen, B.; Pan, Z.; Xie, J.
643 Nanoscintillator-Mediated X-ray Inducible Photodynamic Therapy
644 for In Vivo Cancer Treatment. *Nano Lett.* **2015**, *15*, 2249–2256.
- 645 (24) Lan, G.; Ni, K.; Xu, R.; Lu, K.; Lin, Z.; Chan, C.; Lin, W.
646 Nanoscale Metal–Organic Layers for Deeply Penetrating X-ray-
647 Induced Photodynamic Therapy. *Angew. Chem., Int. Ed.* **2017**, *56*,
648 12102–12106.
- 649 (25) Fan, W.; Tang, W.; Lau, J.; Shen, Z.; Xie, J.; Shi, J.; Chen, X.
650 Breaking the Depth Dependence by Nanotechnology-Enhanced X-
651 Ray-Excited Deep Cancer Theranostics. *Adv. Mater.* **2019**, *31*,
652 1806381.
- 653 (26) Ren, X.-D.; Hao, X.-Y.; Li, H.-C.; Ke, M.-R.; Zheng, B.-Y.;
654 Huang, J.-D. Progress in the Development of Nanosensitizers for X-
655 ray-induced Photodynamic Therapy. *Drug Discovery Today* **2018**, *23*,
656 1791–1800.
- 657 (27) Shrestha, S.; Wu, J.; Sah, B.; Vanasse, A.; Cooper, L. N.; Ma, L.;
658 Li, G.; Zheng, H.; Chen, W.; Antosh, M. P. X-ray induced
659 Photodynamic Therapy with Copper-cysteamine Nanoparticles in
660 Mice Tumors. *Proc. Natl. Acad. Sci. U. S. A.* **2019**, *116*, 16823–16828.
- 661 (28) He, L.; Yu, X.; Li, W. Recent Progress and Trends in X-ray-
662 Induced Photodynamic Therapy with Low Radiation Doses. *ACS*
663 *Nano* **2022**, *16*, 19691–19721.
- 664 (29) Ahmad, F.; Wang, X.; Jiang, Z.; Yu, X.; Liu, X.; Mao, R.; Chen,
665 X.; Li, W. Codoping Enhanced Radioluminescence of Nano-
666 scintillators for X-ray-Activated Synergistic Cancer Therapy and
667 Prognosis Using Metabolomics. *ACS Nano* **2019**, *13*, 10419–10433.
- 668 (30) Bulin, A.-L.; Broekgaarden, M.; Chaput, F.; Baisamy, V.;
669 Garrevoet, J.; Busser, B.; Brueckner, D.; Youssef, A.; Ravanat, J.-L.;
670 Dujardin, C.; Motto-Ros, V.; Lerouge, F.; Bohic, S.; Sancey, L.;
671 Elleaume, H. Radiation Dose-Enhancement Is a Potent Radio-
672 therapeutic Effect of Rare-Earth Composite Nanoscintillators in
673 Preclinical Models of Glioblastoma. *Adv. Sci.* **2020**, *7*, 2001675.
- 674 (31) Liu, Y.; Chen, W.; Wang, S.; Joly, A. G. Investigation of Water-
675 soluble X-ray Luminescence Nanoparticles for Photodynamic
676 Activation. *Appl. Phys. Lett.* **2008**, *92*, 043901.
- 677 (32) Villa, C.; Campione, M.; Santiago-González, B.; Alessandrini,
678 F.; Erratico, S.; Zucca, I.; Bruzzone, M. G.; Forzenigo, L.; Malatesta,
679 P.; Mauri, M.; Trombetta, E.; Brovelli, S.; Torrente, Y.; Meinardi, F.;
680 Monguzzi, A. Self-Assembled pH-Sensitive Fluoromagnetic Nano-
681 tubes as Archetype System for Multimodal Imaging of Brain Cancer.
682 *Adv. Funct. Mater.* **2018**, *28*, 1707582.
- 683 (33) Pope, M.; Swenberg, C. E. *Electronic Processes in Organic*
684 *Crystals and Polymers*; Oxford University Press, 1999; Vol. 39.
- 685 (34) Nair, D. P.; Podgóroski, M.; Chatani, S.; Gong, T.; Xi, W.;
686 Fenolis, C. R.; Bowman, C. N. The Thiol-Michael Addition Click
687 Reaction: A Powerful and Widely Used Tool in Materials Chemistry.
688 *Chem. Mater.* **2014**, *26*, 724–744.
- (35) Northrop, B. H.; Frayne, S. H.; Choudhary, U. J. P. C. Thiol–
689 maleimide “click” Chemistry: Evaluating the Influence of Solvent,
690 Initiator, and Thiol on the Reaction Mechanism, Kinetics, and
691 Selectivity. *Polymers* **2015**, *6*, 3415–3430. 692
- (36) De Luca, G.; Romeo, A.; Villari, V.; Micali, N.; Foltran, I.;
693 Foresti, E.; Lesci, I. G.; Roveri, N.; Zuccheri, T.; Sclaro, L. M. Self-
694 organizing Functional Materials via Ionic Self Assembly: Porphyrins
695 H-and J-aggregates on Synthetic Chrysotile Nanotubes. *J. Am. Chem.*
696 *Soc.* **2009**, *131*, 6920–6921. 697
- (37) Falini, G.; Foresti, E.; Gazzano, M.; Gualtieri, A. F.; Leoni, M.;
698 Lesci, I. G.; Roveri, N. Tubular-shaped Stoichiometric Chrysotile
699 Nanocrystals. *Chem. —Eur. J.* **2004**, *10*, 3043–3049. 700
- (38) Parker, S. F. Vibrational spectroscopy of N-methylmaleimide.
701 *Chem. —Eur. J.* **1995**, *51*, 2067–2072. 702
- (39) Altman, R. S.; Crofton, M. W.; Oka, T. Observation of the
703 Infrared ν_2 band (CH stretch) of Protonated Hydrogen Cyanide
704 HCNH^+ . *J. Chem. Phys.* **1984**, *80*, 3911–3912. 705
- (40) Kim, S.; Fujitsuka, M.; Majima, T. Photochemistry of Singlet
706 Oxygen Sensor Green. *J. Phys. Chem. B* **2013**, *117*, 13985–13992. 707
- (41) Bulin, A.-L.; Vasil'ev, A.; Belsky, A.; Amans, D.; Ledoux, G.;
708 Dujardin, C. Modelling Energy Deposition in Nanoscintillators to
709 Predict the Efficiency of the X-ray-induced Photodynamic Effect.
710 *Nanoscale* **2015**, *7*, 5744–5751. 711
- (42) Procházková, L.; Pelikánová, I. T.; Míhóková, E.; Dědic, R.;
712 Čuba, V. Novel Scintillating Nanocomposite for X-ray Induced
713 Photodynamic Therapy. *Radiat. Meas.* **2019**, *121*, 13–17. 714
- (43) Villa, I.; Moretti, F.; Fasoli, M.; Rossi, A.; Hattendorf, B.;
715 Dujardin, C.; Niederberger, M.; Vedda, A.; Lauria, A. The Bright X-
716 Ray Stimulated Luminescence of HfO_2 Nanocrystals Activated by Ti
717 Ions. *Adv. Opt. Mater.* **2020**, *8*, 1901348. 718
- (44) Hill, R.; Healy, B.; Holloway, L.; Kuncic, Z.; Thwaites, D.;
719 Baldock, C. Advances in Kilovoltage X-ray Beam Dosimetry. *Phys.*
720 *Med. Biol.* **2014**, *59*, R183–R231. 721
- (45) Hachadorian, R. L.; Bruza, P.; Jermyn, M.; Gladstone, D. J.;
722 Pogue, B. W.; Jarvis, L. A. Imaging Radiation Dose in Breast
723 Radiotherapy by X-ray CT calibration of Cherenkov light. *Nat.*
724 *Commun.* **2020**, *11*, 2298. 725
- (46) Lin, J.; Wang, S.; Huang, P.; Wang, Z.; Chen, S.; Niu, G.; Li,
726 W.; He, J.; Cui, D.; Lu, G.; et al. Photosensitizer-loaded Gold Vesicles
727 with Strong Plasmonic Coupling Effect for Imaging-guided Photo-
728 thermal/photodynamic Therapy. *ACS Nano* **2013**, *7*, 5320–5329. 729
- (47) Wu, M.; Guo, H.; Liu, L.; Liu, Y.; Xie, L. J. >Size-dependent
730 cellular uptake and localization profiles of silver nanoparticles<>. *Int.*
731 *J. Nanomed.* **2019**, *14*, 4247–4259. 732